Within oral solid dosage manufacturing for systemic antibacterial therapy, direct encapsulation of (1R,2R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol into hard gelatin capsules is performed at blend bulk densities between 0.45 g/cm³ and 0.62 g/cm³, with the free amino group imposing specific constraints on excipient compatibility. The crystalline API is pre-sieved through an aperture of 500 µm (equivalent to ASTM E11 No. 35 mesh) and combined with pregelatinised starch (USP/NF) at a 1:1.5 (w/w) ratio to suppress segregation during 20-minute bin blender rotation at 15 rpm in a 300 L V-type blender. Blend uniformity is evaluated per USP Chapter <905> Phase 2 acceptance criteria, requiring an RSD below 6.0% across 10 sampling locations, and assay acceptance per ICH Q2(R1) with related substances controlled below 0.5% per ICH Q3B(R2) reporting thresholds. The formulation matrix incorporates microcrystalline cellulose (USP/NF) at 18–22% w/w, sodium starch glycolate at 2.0–4.0% w/w as superdisintegrant, and magnesium stearate (USP/NF) at 0.75–1.0% w/w introduced by external lubrication during the final 3 minutes of blending to prevent over-lubrication, a known failure mode observed on production lines where extended blending above 10 minutes produces capsular slug hardness below 4 kN and incomplete ejection. Dissolution acceptance per USP Chapter <711> using Apparatus II (paddle) at 50 rpm in 900 mL of 0.1 N hydrochloric acid requires Q = 80% within 45 minutes, although published data for this specific configuration under neutral media conditions remains limited. Encapsulation is carried out on a 12-station automatic capsule filler equivalent to Bosch GKF 2600 or MG2 Planeta, operating at 60,000 capsules/hour with compacted slug weight of 420–480 mg net fill per size-0 capsule. Terminal product types include 250 mg and 500 mg potency hard gelatin capsules and HPMC vegetarian capsule variants for halal- and vegetarian-compliant markets, with batch-to-batch weight variation controlled to ±3.0% per USP Chapter <2091>.

Pharmacopoeial compliance for this oral solid dosage stream requires alignment with FDA 21 CFR 211.67 (equipment cleaning), ICH Q3D Step 4 elemental impurity limits as implemented through USP Chapter <232> and <233>, and residual solvent control per USP Chapter <467> with a Class 2 solvent limit of 600 ppm for methanol. The free amino moiety of the API generates a measurable pH shift within the capsule microenvironment to approximately pH 8.0–8.5, which accelerates hydrolytic degradation of gelatin shell cross-linking agents; therefore, shell moisture content is maintained at 13.0–15.0% (as determined by loss on drying at 105°C) and storage conditions at 25°C/60% RH are mandated. Table 1 provides the comparative dissolution profile across formulation gradient variants produced during development-scale optimisation.

When Paediatric Oral Suspension Granules Require Humidity-Tolerant Dose Uniformity

At relative humidity values above 60%, wet granulation of paediatric oral suspension intermediates containing (1R,2R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol demands controlled-viscosity aqueous binder systems to prevent agglomeration collapse and dose uniformity drift exceeding the USP Chapter <905> acceptance limit of 15.0% RSD. The API is incorporated at 20–35% w/w of the granule blend, with a nominal concentration equivalent to 125 mg/5 mL after reconstitution with purified water to a final volume of 60 mL or 100 mL. Aqueous binder solutions containing povidone K-30 (USP/NF) at 2.0–3.0% w/w of dry granule mass are introduced via a peristaltic pump at 50–80 g/min into a 150 L high-shear granulator (equivalent to Glatt GRAL-150 or Fielder PMA 150) with impeller speed of 180–220 rpm and chopper speed of 1,200 rpm. Wet mass end-point is determined by impeller torque inflection, typically occurring at 6.0–8.0 N·m, beyond which over-granulation produces D50 growth above 600 µm and subsequent reconstitution sedimentation ratios below 0.85. Drying is performed in a fluid bed dryer equivalent to Glatt GPCG 5, inlet temperature 55°C ± 5°C, dew point below 8°C, until loss on drying reaches 1.5–2.5%. Sieving through an ASTM E11 No. 20 (841 µm) screen is followed by blending with xanthan gum (USP/NF) at 1.0–2.0% w/w to provide suspension viscosity of 150–300 mPa·s at 25°C upon reconstitution. Terminal product types include unit-dose sachets of 2.5 g granule mass and bulk bottles with graduated dosing syringes. Compliance is anchored to USP Chapter <795> for compounding of non-sterile preparations, Ph. Eur. 2.9.12 for uniformity of mass of single-dose preparations, and ICH Q3D for elemental impurities. The free amino group of the API exhibits Maillard-type interaction potential with reducing sugar excipients; therefore, sucrose is excluded and mannitol (USP/NF) at 55–65% w/w is substituted as the bulking agent, with published stability data confirming absence of browning reactions over 24 months at 25°C/60% RH.

What Controls Sterile Filtration Flux in Aqueous Injectable Solutions?

Because the API exhibits pH-dependent aqueous solubility that rises sharply below pH 4.5 due to protonation of the primary amino group, sterile filtration of aqueous injection solutions requires careful buffering at pH 5.0–6.5 using citrate-phosphate buffer at 10–50 mM ionic strength. The free base solubility in water at 25°C is approximately 2.5 mg/mL; formulation as the hydrochloride salt raises this to 50–80 mg/mL. For intravenous and intramuscular administration, the API is incorporated at 1.0–8.0% w/v expressed as free base equivalent, with the hydrochloride salt prepared in situ by titration with 0.1 N hydrochloric acid to a final pH of 5.5–6.0. Terminal sterilisation is evaluated per Ph. Eur. 5.1.1 and USP Chapter <1211>, with steam sterilisation at 121°C for 15 minutes validated to achieve a sterility assurance level (SAL) of 10⁻⁶. However, the nitroaromatic chromophore of the molecule degrades above 60°C in aqueous alkaline conditions, so autoclave loading patterns are restricted to ≤100 vials per load with air-over-pressure cooling ramps not exceeding 2.0°C/min. Sterile filtration is performed through 0.22 µm PVDF or PES membrane cartridges with effective filtration area of 0.6 m² per 50 L batch, maintaining a transmembrane pressure below 1.0 bar to prevent flux collapse evidenced by dropping flow rates from 12 L/min to below 3 L/min within 10 minutes at 20°C when membrane fouling by nitroaromatic aggregates occurs. Aseptic filling under ISO Class 5 laminar airflow per ISO 14644-1 into Type I amber borosilicate glass vials (USP <660>) of 10 mL and 20 mL nominal fill volume is undertaken with headspace nitrogen purging to below 2.0% v/v oxygen. Terminal product types include single-dose vials, multi-dose vials with benzyl alcohol at 0.9% v/v, and ampoules. Table 2 summarises the compliance checklist for this injectable stream.

Ophthalmic Ointment Rheology and Micronised API Distribution

For ophthalmic ointment production at 70–75°C processing temperature, levigation of micronised (1R,2R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol into anhydrous wool fat and liquid paraffin bases must achieve particle size D90 below 20 µm to prevent corneal abrasion and to satisfy USP Chapter <771> ophthalmic ointment uniformity. The API is incorporated at 0.5–1.0% w/w for therapeutic antifungal-bacterial application, with the free base micronised to D50 of 5–8 µm using a spiral jet mill operated at 4–6 bar compressed nitrogen, classifier speed 6,000–8,000 rpm, and feed rate of 2.0–3.0 kg/h. The micronised powder is levigated with sterile liquid paraffin (USP/NF) at a 1:3 (w/w) ratio to form a smooth paste, then incorporated portion-wise into the molten anhydrous base consisting of white petrolatum (60–70% w/w), liquid paraffin (20–30% w/w), and wool fat (8–10% w/w) at 70°C. Deaeration is performed under vacuum of −0.85 bar for 30 minutes in a jacketed vacuum mixer (equivalent to FrymaKoruma VE-100), with residual air bubble content below 0.5% v/v. The ointment is filled into sterile aluminium or HDPE ophthalmic tubes of 3.5 g and 5.0 g net weight on a tube filler operating at 40–60 tubes/min, with sealing at 160–180°C for aluminium tubes. Terminal product types include 3.5 g ophthalmic ointment tubes for single-patient use and 5.0 g clinical trial packaging. Compliance is anchored to Ph. Eur. 2.9.5 for uniformity of mass of single-dose preparations, USP Chapter <771> for ophthalmic ointments, and WHO GMP Annex 3 for sterile pharmaceutical products, with sterility per USP Chapter <71> verified on each manufactured batch. Validation of the rheology requires that the filled ointment maintain viscosity between 1,500 mPa·s and 3,500 mPa·s at 25°C measured by cone-plate viscometry at 10 s⁻¹, preventing tube extrusion failure while allowing eyelid shear distribution below 150 Pa yield stress.

Aseptically filling ophthalmic solutions of the API into low-density polyethylene dropper bottles at 0.5% w/v concentration is performed within ISO Class 5 cleanroom environments with EU GMP Annex 1 compliance, requiring that the sterile-filtered solution exhibit no flux decline exceeding 30% over the filtration cycle. The solution is prepared by dissolving the hydrochloride salt of the API in water for injection (WFI) at 5.0 g/L, adjusted to pH 5.5–6.0 with dilute hydrochloric acid, and isotonicised with sodium chloride at 0.9% w/v to achieve osmolality of 280–320 mOsm/kg. Boric acid-borate buffer at 0.5% w/v is incorporated to maintain pH stability over the 24-month shelf life, and benzalkonium chloride (USP/NF) at 0.01% w/v serves as antimicrobial preservative per USP Chapter <51> antimicrobial effectiveness testing. Sterile filtration through 0.22 µm PVDF cartridge filters with 0.45 µm pre-filtration is performed at 10–15°C to suppress microbial growth during processing. Terminal product types include 5 mL and 10 mL LDPE dropper bottles with tamper-evident closures, multi-dose vials for institutional use, and single-use unit-dose containers of 0.4 mL. Compliance includes USP Chapter <789> for ophthalmic solutions, Ph. Eur. 2.9.6 for uniformity of content, and ISO 14644-1 for cleanroom classification, with environmental monitoring limits of ≤ 3,520 particles/m³ for ≥ 0.5 µm particles in ISO Class 5.

Topical Dermatological Incorporation into Anhydrous Hydrocarbon Bases

To incorporate the API into anhydrous dermatological bases without recrystallisation during cooling, high-shear dispersion followed by triple roller milling is required at API concentrations of 0.5–1.0% w/w for topical antibacterial applications where the free base crystalline form is dispersed in white petrolatum-mineral oil matrices. The crystalline powder is first dispersed into mineral oil (USP/NF) at 70°C using a high-shear disperser (equivalent to IKA Ultra-Turrax T-50 digital) at 5,000–8,000 rpm for 20 minutes, producing a pre-dispersion that is then incorporated into the molten ointment base consisting of white petrolatum (80–85% w/w), mineral oil (10–15% w/w), and microcrystalline wax (3–5% w/w). The molten mixture is cooled to 40–45°C and passed through a triple roller mill (equivalent to EXAKT 80E Plus) with roller gap settings of 10 µm (first pass), 5 µm (second pass), and 2 µm (third pass) to achieve final particle size D90 below 15 µm. Batch size on production scale is typically 25–50 kg, and the milling process generates measurable temperature rise of 3–5°C per pass, which must be monitored to prevent degradation of the nitroaromatic API above 60°C. Terminal product types include 15 g and 30 g aluminium tubes, 50 g polypropylene jars, and unit-dose sachets of 2 g. Compliance is anchored to Ph. Eur. 4.1.1 for semi-solid preparations, USP Chapter <3> for topical preparations, and ICH Q3C for residual solvent limits, with residual solvent levels from milling lubricants controlled below 50 ppm. Incompatibility exists with amine-functionalised emulsifying agents such as triethanolamine stearate, which accelerates oxidative degradation of the API through alkaline-catalyzed nitro group reduction; therefore, non-ionic emulsifying waxes (USP/NF) at 5–8% w/w are substituted when a water-in-oil cream rather than an anhydrous ointment is specified.

Compounding Otic Preparations for Pseudomonas-Positive Otitis Externa

Compounded under ISO Class 5 laminar airflow, otic suspensions containing 0.5% w/v of the micronised API are prepared by geometric dilution of the 5–10 µm D50 powder into the anhydrous vehicle of propylene glycol (USP/NF) at 40–50% v/v and glycerin (USP/NF) at 15–25% v/v, with the balance consisting of phosphate-buffered saline adjusted to pH 5.5. The API is incorporated at 5.0 mg/mL expressed as free base, with the suspension stabilised by the inclusion of hydroxyethyl cellulose (USP/NF) at 0.3–0.5% w/v to achieve apparent viscosity of 80–120 mPa·s at 25°C. The compounding process follows USP Chapter <795> for non-sterile preparations and USP Chapter <797> for sterile compounding risk level assessment, with sterile filtration of the vehicle through 0.22 µm PVDF membranes prior to aseptic suspension of the pre-sterilised micronised API. Terminal product types include 10 mL amber glass dropper bottles with sterile dropper tips, and unit-dose 1 mL LDPE ampoules for single-instillation use in otology clinics. The clinical relevance of this formulation for Pseudomonas aeruginosa otitis externa is established through susceptibility testing per CLSI M100-S32 with minimum inhibitory concentration ranges of 2–8 µg/mL for wild-type isolates. Operational boundaries include exclusion of formulations containing hydrogen peroxide or iodine-based antiseptics due to rapid oxidative degradation of the nitrophenyl moiety, and storage at 2–8°C when compounded for extended-use beyond 14 days. Compliance with Ph. Eur. 2.9.10 for uniformity of content of single-dose preparations is verified on each compounded batch, with particle size distribution confirmed by laser diffraction per ISO 13320:2020.

For finished-product manufacturers procuring (1R,2R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol as a pharma-grade API, the critical material attributes specified at release include optical rotation [α]D²⁰ of +22.0° to +24.5° (c = 1.0, methanol), chiral purity not less than 98.5% enantiomeric excess by chiral HPLC per Ph. Eur. 2.2.29, residual water by Karl Fischer titration below 0.5%, residue on ignition below 0.10% per USP Chapter <281>, and related substances with any single unspecified impurity below 0.10% per ICH Q3A(R2) thresholds for a 2 g/day maximum daily dose. The API must be stored in light-resistant containers under nitrogen at 15–25°C, with retest period of 24 months supported by real-time stability data generated under ICH Q1A(R2) conditions and intermediate condition of 30°C/65% RH for Zone III/IV markets.